The Brazilian National Technical Commission on Biosafety (CTNBio) has approved the commercial release of the hybrid maize variety containing the genetic events MON 87427 × MON 95379 × MIR162 × MON 88017. The events are already individually approved for commercial release in the country, and CTNBio concluded by deferral for the commercial release of the variety and any other activities related to this and any progenies derived from it, as well as its exemption from monitoring post-commercial release.

Having already approved the individual genetic events, CTNBio found no evidence of potential synergistic or antagonistic effects resulting from the combination of the genetic events. CTNBio indicated that the insecticidal proteins expressed in MON 87427 × MON 95379 × MIR162 × MON 88017 maize do not interact and that there is no indication that their combination is likely to result in unexpected interactions. Furthermore, the CTNBio cited a substantial body of knowledge generated in published and unpublished interaction studies, including the Vip3Aa20 protein and several other B.t proteins tested in combination, which provides strong weight of evidence that the proteins Cry1Da_7/Cry1B.868 and Vip3Aa20 and Cry1Da_7/Cry1B.868 and Cry3Bb1 are unlikely to interact and cause adverse effects to the environment and human and animal safety.